Archives

Choose a date range

From To

Choose one or more categories

Categories:



Show only original CenterWatch stories

 


Alnylam, Isis extend decade-long partnership for RNA therapeutics

Tuesday, January 13, 2015 09:00 AM

Isis Pharmaceuticals, based in Carlsbad, Calif., and Alnylam Pharmaceuticals, based in Cambridge, Mass., have formed a new agreement, extending their existing strategic partnership—formed originally in 2004—to lead the development and commercialization of RNA therapeutics.

More... »


Oracle launches data capture solution that integrates adherence data

Tuesday, January 13, 2015 08:30 AM

Oracle has introduced Oracle Health Sciences InForm Medication Adherence Insights Cloud Service. This solution not only enables sponsors to automatically capture precise and timely data about medication adherence, it also can help accelerate insight about drug efficacy and safety and speed clinical trials, which can, in turn, increase trial success rates.

More... »


Covance to vote on proposed acquisition by LabCorp Feb. 18

Tuesday, January 13, 2015 08:00 AM

CRO Covance has set a date for a special meeting of its stockholders to consider and vote on the previously announced proposed acquisition of Covance by Laboratory Corporation of America Holdings (LabCorp) and certain other related matters. The special meeting will be held Feb. 18, at 8 a.m., in Princeton, N.J.

More... »

Roche to acquire majority ownership of Foundation Medicine

Monday, January 12, 2015 02:44 PM

Foundation Medicine (FMI), based in Cambridge, Mass., and Roche will enter into a broad strategic collaboration to further advance Foundation Medicine's position in molecular information and genomic analysis while providing Roche a unique opportunity to optimize the identification and development of novel treatment options for cancer patients. Roche also will acquire majority ownership of Foundation Medicine.

More... »

Incyte, Agenus ink global alliance to develop novel immuno-oncology antibodies

Monday, January 12, 2015 02:42 PM

Incyte, a Wilmington, Del.-based biopharmaceutical company, and Agenus, an immuno-oncology company based in Lexington, Mass., have formed a global license, development and commercialization agreement focused on novel immuno-therapeutics using Agenus' proprietary Retrocyte Display antibody discovery platform.

More... »

X-Chem collaborates with Janssen and Johnson & Johnson Innovation

Monday, January 12, 2015 02:40 PM

X-Chem, a privately held biotechnology company based in Waltham, Mass., applying its drug discovery platform to the generation of novel small molecule therapeutics, has announced a multi-target collaboration with Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.  The collaboration, which is being facilitated by Johnson & Johnson Innovation, Boston, focuses on the discovery and development of candidate molecules for the treatment of inflammatory diseases.

More... »

Shire to acquire NPS Pharma for $5.2 billion

Monday, January 12, 2015 02:38 PM

Dublin, Ireland-based Shire and NPS Pharmaceuticals have entered into a merger agreement, under which Shire will acquire all outstanding shares of NPS Pharma for $46 per share in cash, for a total consideration of approximately $5.2 billion.

More... »

Novella Clinical, Cardiovascular Research Foundation collaborate, provide clinical trial expertise

Monday, January 12, 2015 02:37 PM

Novella Clinical, a Quintiles company, and the Cardiovascular Research Foundation (CRF), an independent, academically focused nonprofit organization based in New York, have announced a preferred provider collaboration that will offer a set of clinical trial services to developers of cardiovascular drugs and devices.

More... »

CluePoints tests SaaS solution, partners with Iperion

Monday, January 12, 2015 02:35 PM

CluePoints, a Cambridge, Mass.-based provider of Centralized Statistical Monitoring (CSM) solutions for clinical trials, has announced that a web-based version of its intelligent risk-based monitoring (RBM) platform is being successfully tested by a number of key pharmaceutical sponsors, demonstrating new opportunities for the industry by providing users with complete control over the analysis of their clinical trial data.

More... »

Evotec, Padlock Therapeutics extend collaboration

Monday, January 12, 2015 02:32 PM

Evotec, a Germany-based drug discovery alliance and development partnership company, and Padlock Therapeutics, a private, Cambridge, Mass.-based biotechnology company dedicated to creating new medicines to treat destructive autoimmune diseases, have successfully completed an initial goal in a program focused on developing inhibitors of protein-arginine deiminases (PADs) and have further extended the collaboration that was first signed in January 2014.

More... »

CenterWatch Drugs in Clinical Trials
CWWeekly

January 26

2015 CRO outlook: M&As, IPOs, strategic partnerships and increased eClinical outsourcing expected to continue

IOM, industry stakeholders propose standards, guidelines for open sharing of clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs